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Mendelian Randomisation study of 
the influence of eGFR on coronary 
heart disease
Pimphen Charoen1,2, Dorothea Nitsch1, Jorgen Engmann3, Tina Shah3, Jonathan White4, 
Delilah Zabaneh5, Barbara Jefferis6, Goya Wannamethee6, Peter Whincup7, Amy Mulick 
Cassidy1, Tom Gaunt8, Ian Day8, Stela McLachlan9, Jacqueline Price9, Meena Kumari10,11, 
Mika Kivimaki11, Eric Brunner11, Claudia Langenberg12,13, Yoav Ben-Shlomo14, 
Aroon Hingorani3, John Whittaker1,15, Juan Pablo Casas1,12,  Frank Dudbridge1 & the UCLEB 
Consortium# 
Impaired kidney function, as measured by reduced estimated glomerular filtration rate (eGFR), has 
been associated with increased risk of coronary heart disease (CHD) in observational studies, but it 
is unclear whether this association is causal or the result of confounding or reverse causation. In this 
study we applied Mendelian randomisation analysis using 17 genetic variants previously associated 
with eGFR to investigate the causal role of kidney function on CHD. We used 13,145 participants 
from the UCL-LSHTM-Edinburgh-Bristol (UCLEB) Consortium and 194,427 participants from the 
Coronary ARtery DIsease Genome-wide Replication and Meta-analysis plus Coronary Artery Disease 
(CARDIoGRAMplusC4D) consortium. We observed significant association of an unweighted gene 
score with CHD risk (odds ratio = 0.983 per additional eGFR-increasing allele, 95% CI = 0.970–0.996, 
p = 0.008). However, using weights calculated from UCLEB, the gene score was not associated with 
disease risk (p = 0.11). These conflicting results could be explained by a single SNP, rs653178, which was 
not associated with eGFR in the UCLEB sample, but has known pleiotropic effects that prevent us from 
drawing a causal conclusion. The observational association between low eGFR and increased CHD risk 
was not explained by potential confounders, and there was no evidence of reverse causation, therefore 
leaving the remaining unexplained association as an open question.
Chronic kidney disease (CKD) occurs in 15–20% of the general population aged 65 years or older. Markers of 
CKD, such as a low estimated glomerular filtration rate (eGFR) and/or elevated Urine Albumin Creatinine Ratio 
(UACR), are major independent risk factors for cardiovascular and all-cause mortality1,2. In particular, people 
with lower eGFR are at a higher risk of developing coronary heart disease (CHD).
Although it has been proposed that CKD may be causally associated with CHD, the precise biological path-
ways for this association are not well understood, and hypotheses regarding this finding are varied, broadly 
involving inflammatory pathways and/or vascular calcification3–6. Currently, people with CKD are treated with 
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blood pressure lowering drugs and statins to prevent poor outcomes. However, many genetic variants that are 
associated with high blood pressure are not associated with eGFR or CKD7, as might be expected if they were 
on the same causal pathway to CHD. Also, there is little overlap in association between CKD and CHD genetic 
variants and early markers of cardiovascular disease, which would be expected if kidney function were causally 
related to CHD8.
People with CKD tend to have had adverse early life circumstances that predispose them to cardiovascular 
disease9–11, and individuals who are overweight at earlier age are more likely to have CKD at older age suggesting 
that CKD is a marker or consequence of a cumulative adverse life style. Hence, it is not yet clear whether low 
kidney function directly causes CHD or whether the observed association is due to other shared risk factors/
confounders, in particular socioeconomic status, early life risk factors and unhealthy lifestyle.
Here we applied Mendelian Randomisation (MR) to determine whether lower eGFR per se has a causal role 
to contribute to later CHD. To our knowledge, this is the first MR study to explicitly investigate the influence of 
eGFR on CHD. Previously, Olden et al. studied whether several genetic variants affect both eGFR and CHD8. 
They identified one SNP, rs653178 that was associated with both; but while this is consistent with a causal effect, 
they did not consider whether it met the assumptions required for MR nor did they estimate a causal effect size. 
Here we go further by combining 17 SNPs into a single gene score, which can improve the power of MR studies 
when individual SNPs are not significantly associated with the outcome12, and we use a richly phenotyped data 
set, the UCLEB consortium13 to thoroughly examine the possibility of violating the MR assumptions through 
confounding or pleiotropy.
Research design and methods
Study design. We used data from two consortia, UCLEB13 and CARDIoGRAMplusC4D14–16. The former 
allowed assessment of the MR assumptions for eGFR, namely that the gene score is associated with eGFR, not 
associated with potential confounders of the eGFR-CHD association, and not associated with other biomark-
ers of CHD that might represent alternative pathways than that through eGFR. In UCLEB, we used individual 
patient data from 2,249 cases of CHD and 10,896 controls from 7 cohort studies: the British Regional Heart Study 
(BRHS), British Women’s Heart and Health Study (BWHHS), Caerphilly Prospective Study (CAPS), Edinburgh 
Type-2 Diabetes Study (ET2DS), Edinburgh Artery Study (EAS), English Longitudinal Study of Ageing (ELSA), 
and Whitehall II Study (WHII). Four studies (BRHS, BWHHS, CAPS, and ET2DS) have eGFR available. UCLEB 
has 116 phenotypes related to cardiovascular function, allowing SNPs to be thoroughly assessed for validity of 
the MR assumptions.
The CARDIoGRAMplusC4D consortium provides a large sample for assessing genetic association with CHD. 
The Consortium released summary statistics from 3 meta-analyses of coronary artery disease: CARDIoGRAM 
genome-wide association study (GWAS) with 22,233 CHD cases and 64,762 controls16, C4D GWAS with 
15,420 CHD cases and 15,062 controls15, and the combined data of these two GWAS with additional cohorts, 
CARDIoGRAMplusC4D Metabochip, with 63,746 CHD cases and 130,681 controls14. These consortia data allow 
the assessment of genetic association with CHD in very large samples, but do not provide information on eGFR.
Selection of SNPs and construction of gene score. We identified 32 SNPs previously reported to be 
associated with eGFR (S1 Table). Seventeen of them, which are not in linkage disequilibrium (LD) and have been 
genotyped in UCLEB, were shortlisted as potential components of an instrument for MR (S2 Table) because they 
could be investigated for validity of the MR assumptions using the UCLEB data. Due to the different genotyp-
ing platforms used in CARDIoGRAM GWAS, C4D GWAS, and CARDIoGRAMplusC4D Metabochip, our 17 
selected SNPs are not always available in all 3 meta-analyses. Thus the total sample sizes vary across SNPs used to 
investigate association with CHD (S1 Fig).
These selected SNPs were then combined into gene scores. Two types of gene score were used: 1) unweighted 
gene score, defined for subject i as = ∑S gi j ij where gij is the count of eGFR-increasing alleles for subject i at SNP 
j with the direction of effect taken from the UCLEB data, and 2) weighted gene score, = ∑S w gi j j ij, which 
includes estimates of effects on eGFR, wj, at each SNP based on the UCLEB data. More precisely, the wj are the 
estimates from linear regression analyses of eGFR on SNP j, under additive genotypic coding.
Exposure and outcome variables. Our primary outcome is CHD (defined as fatal or non fatal myocardial 
infarction, or revascularization, from both diagnosis validation and self-report) and the exposure is the level of 
kidney function measured by eGFR. In the UCLEB data, we derived eGFR based on creatinine using the modifi-
cation of diet in renal disease (MDRD) model17
. = ∗ . ∗
∗ ∗ .
− .
− .
GFR ml m creatinine umol L
age if female
( /min/1 73 ) 175 (0 011312 ( / ))
( ) (0 742 ) (1)
2 1 154
0 203
eGFR was normally distributed in our data, therefore no further transformation was applied.
Potential confounding factors. From the total of 116 traits available in UCLEB, we systematically checked 
for potential confounding factors across 94 traits measured in up to 7 studies. We identified potential confounders 
by testing each of these traits for both eGFR-trait (available in 4 studies) and CHD-trait associations. As the pres-
ence of both associations is necessary but not sufficient to establish confounding, we considered those associated 
traits as potential confounding factors, unless there is additional external evidence that a particular biomarker 
is renally cleared, i.e. potentially on the causal pathway between kidney function and CHD. For the eGFR-trait 
and CHD-trait associations we controlled the false discovery rate at 0.05 by the Benjamini-Hochberg proce-
dure. We used a permutation procedure to check whether correlation among traits would cause this procedure 
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to be conservative, finding that the overall level of correlation is negligible in this context (see Supplementary 
Methods).
SNP instrument validity. We used UCLEB data to test the validity of our gene scores as instrumental var-
iables under the three MR assumptions: 1) association between gene scores and eGFR, 2) absence of association 
between gene scores and common causes of eGFR and CHD, and 3) absence of pathways between gene scores 
and CHD other than through eGFR. We tested assumption 1 using linear regression of eGFR on the gene scores, 
assumption 2 using linear regression of each identified potential confounder on the gene scores (except gender 
where logistic regression was applied), and assumption 3 using linear regression of each trait in UCLEB (whether 
or not a potential confounder) on the gene scores. Each regression adjusted for study as a categorical covariate. 
We controlled the false discovery rate at 0.05 by the Benjamini-Hochberg procedure.
Mendelian Randomisation. We tested for a causal effect by testing the association between each gene score 
and CHD and appealing to the MR principle. As only summary odds ratios and their standard errors were availa-
ble from the CHD consortia, we applied the Johnson formula described by Burgess et al.12, in which the regression 
coefficient of the gene score on CHD is
β
β
=
∑
∑
−
−
ˆ
ˆw s
w s (2)
YS
j j Yj Yj
j j Yj
2
2 2
with standard error 
∑ −w s
1
j j Yj
2 2
, where βˆYj is the estimated log odds ratio of SNP j on CHD, sYj is its standard error, 
and wj is a predetermined weight. The unweighted score has wj = 1 for all SNPs, whereas the weighted score sets 
wj to the linear regression coefficient of SNP j for eGFR, here estimated from the UCLEB data (weights and odds 
ratios were calculated for the eGFR increasing alleles). This is an example of two-sample Mendelian randomiza-
tion18 in which the exposure and outcome associations are measured in different samples. Two-sided tests of 
association were performed by comparing the ratio of βˆYS and its standard error to a standard normal 
distribution.
Using the weighted score, βˆYS is an estimate of the causal effect of eGFR on CHD, but we avoid this interpreta-
tion as our aim here was merely to detect the presence of a causal effect.
Reverse Mendelian Randomisation. We considered whether a causal effect exists in the opposite direc-
tion, with CHD acting to cause reduced kidney function. We constructed an weighted gene score from 51 SNPs 
associated with CHD at genome-wide significance, as reported by CARDIoGRAMplusC4D14 and tested this score 
for association with eGFR in the UCLEB data using summary odds ratios as above.
Results
A summary of CHD cases and controls in UCLEB is shown in Table 1. As expected, we observed that eGFR is 
significantly negatively associated with CHD (OR = 0.984 per ml/min/1.73 m2 increase, 95% CI = 0.979–0.988, 
p = 1.98 × 10−12) across its entire range and particularly when comparing subjects with reduced (< 60 ml/
min/1.73 m2) eGFR to those in the intermediate (60–90 ml/min/1.73 m2), and normal/high range (≥ 90 ml/
min/1.73 m2, Fig. 1), consistent with previous studies of the MDRD eGFR-CHD association19.
From 94 traits available in 7 UCLEB studies, we identified 28 potential confounding factors of the eGFR-CHD 
association (Fig. 2, S4 Table). These are generally concordant with previously observed correlates of eGFR and 
risk factors for CHD19. Some discrepancies, for example blood pressure and smoking (ever/never), which were 
not associated with eGFR in UCLEB are likely due to the cross-sectional nature of the data, and have been pre-
viously seen in other data20. One of the potentially confounding factors was NTproBNP, which is known to be 
renally cleared6. NTproBNP was therefore considered to be a variable on the causal pathway between eGFR and 
CHD and not a confounding variable. We also excluded percentage body fat because this was only available in the 
ET2DS study, which did not have many of the other confounders measured. Due to missing data in the remain-
ing 26 potential confounders, we then investigated the observational association between eGFR and CHD in a 
reduced sample size of 1547 (OR = 0.977 per 1 ml/min/1.73 m2 increase, 95% CI = 0.965–0.989, p = 3.38 × 10−4). 
N (available CHD) N (available eGFR) Mean age % Male
Mean eGFR  
(ml/min/1.73m2)
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
BRHS 630 1823 619 1802 69.2 68.8 100 100 61.9 63.7
BWHHS 338 1686 330 1647 71.3 70.6 0 0 60.2 63.5
CAPS 354 1040 343 974 57.0 56.7 100 100 69.8 69.2
ET2D 227 830 223 826 69.0 67.6 73.1 45.5 63.6 72.1
EAS 185 670 0 0 70.8 69.7 57.8 46.3 NA NA
ELSA 316 1669 0 0 75.4 73.3 65.2 50.7 NA NA
WHII 199 3178 0 0 63.3 60.6 85.4 75.0 NA NA
Table 1.  Descriptive table for CHD cases and controls in 7 studies.
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After adjusting for 26 potential confounders, the association between eGFR-CHD was slightly attenuated and 
remained borderline significant (OR = 0.868 per 10 ml/min/1.73 m2 increase, 95% CI = 0.760–1.000, p = 0.05).
In UCLEB, the combination of 17 SNPs explained 1.5% of the variation in eGFR. The corresponding F statistics 
were 59 and 91 for unweighted and weighted scores respectively, indicating that the gene score is a strong instru-
ment. In testing for association between gene scores and all traits available in UCLEB (Fig. 3), our gene scores 
showed an exclusive association with kidney function measurements, including eGFR (adjusted p = 2.0 × 10−12 
and p = 3.3 × 10−19 for unweighted and weighted gene scores respectively), creatinine (adjusted p = 6.0 × 10−9 
and p = 6.8 × 10−16), and serum urea concentration (adjusted p = 9.8 × 10−3 and p = 3.1 × 10−5). This confirms 
the first MR assumption that our gene scores are indeed a good proxy for kidney function. Secondly, associations 
between our gene scores and 26 potential confounding factors and NTproBNP were not significant, meeting the 
second MR assumption that our gene scores are not associated with common causes of eGFR and CHD. Although 
we cannot be sure that our gene scores are not associated with unmeasured confounders, these results (includ-
ing many of the strongest biomarkers for CHD) suggest that any such confounding is weak. Lastly, association 
between our gene scores and other traits available in UCLEB do not reach significance. Therefore our gene scores 
appear specific to eGFR and other kidney-related traits.
We found significant association of the unweighted score with CHD (OR = 0.983 per additional eGFR increas-
ing allele, 95% CI = 0.970–0.996, p = 0.008), suggesting a causal effect of eGFR on CHD. This was in the direction 
Figure 1. Association between baseline eGFR and CHD in quintiles (left), and comparing low and 
moderate eGFR to normal/high eGFR (right), in the UCLEB data (1515 cases, 5247 controls). 
Figure 2. Benjamini-Hochberg adjusted P-values for CHD-trait and eGFR-trait (N range of CHD-
trait = 139-13145, and N range of eGFR-trait = 138-6764). Horizontal line shows adjusted P = 0.05.28 
traits significantly associated with both CHD and eGFR on dotted vertical lines are identified as potential 
confounding factors: age, alcohol, body mass index, ECG Cornell product, cotinine, CRP, D-Dimer, 
Eosinophils, factor VIII, Factor IX, FEV1, fibrinogen, FVC, HDL, IL-6, Neutrophil, percentage body fat, 
peak expiratory flow rate, NT-proBNP, ECG QTc, ECG QT interval, sex, total serum protein concentration, 
Triglyceride, tPa, von Willebrand factor, waist circumference, weight. Abbreviations used in the figure are 
defined in S3 Table.
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to that seen in the observational data. However, the association was not significant when using a weighted score 
(OR = 0.993, 95% CI = 0.984–1.002, p = 0.11). Inspection of the weights given to the individual SNPs suggested 
that these results could be explained by rs653178 alone. Previously, it has been shown that there is little overlap 
between well-validated SNPs for kidney disease and CHD, where only rs653178 was highly associated with both 
cystatin-C-based eGFR and CHD21. However this was not the case in UCLEB, in which rs653178 was not asso-
ciated with eGFR and received the smallest weight among all 17 instrument SNPs (S6 Table). Therefore, using 
weights from UCLEB diminished evidence of a causal association observed with the unweighted score.
The unweighted gene score was further investigated to assess the sensitivity of the observed nominal evidence 
of a causal association. We first excluded rs1260326, which has known pleiotropic effects22, and observed the same 
association signal remaining (OR = 0.991, 95% CI = 0.981–1.001, p = 0.003). Secondly we excluded rs653178 
which could have stronger effect through cystatin-based eGFR instead of creatinine-based eGFR22 from the gene 
score, and found that the evidence of causal effect disappeared (OR = 0.994, 95% CI = 0.982–1.005, p = 0.291). 
This implies that rs653178 is driving the significant association of the gene score with CHD. To confirm this, we 
excluded each of the 17 SNPs at a time, and observed that only the exclusion of rs653178 removed the association 
signal. In addition, instead of identifying the eGFR increasing alleles from the UCLEB data, we incorporated 
external information on the direction of effect for 9 SNPs that were available in Olden et al., to allow more accu-
rate estimates due to their larger sample size. While the eGFR increasing alleles in UCLEB are retained for the 
remaining SNPs, for 3 out of the 9 SNPs from Olden et al. a different eGFR increasing allele was identified in com-
parison to UCLEB (S6 Table). After adjusting the unweighted score accordingly, the evidence of a causal effect 
remained (OR = 0.971, 95% CI = 0.950–0.992, p = 0.007).
We further investigated the case in which eGFR < 60 ml/min/1.73 m2 (stage 3 nephropathy) which has been 
significantly associated with increased CHD events23,24. If there is a causal influence of eGFR on CHD, it may be 
stronger in those for whom an increased association is observed. By conditioning on eGFR, a biased estimate of 
causal effect may result25. However, we observed little evidence of a causal association between eGFR and CHD 
with the unweighted score (OR = 0.982, 95% CI = 0.963–1.002, p = 0.083) and the weighted score (OR = 0.991, 
95% CI = 0.974–1.008, p = 0.286) when restricting analysis to subjects with eGFR <  60.
Since the gene scores were not specific to eGFR but also associated with other kidney function traits, we 
adjusted the regression of CHD on eGFR for creatinine and serum urea concentration in the UCLEB data alone. 
Neither gene score was significantly associated with CHD in the UCLEB data, with or without adjustment for 
creatinine and serum urea concentration.
Finally, the reverse MR did not show an association of the CHD gene score with eGFR (β = − 0.120, 95% 
CI = − 1.271–0.872, p = 0.715).
Discussion
We applied Mendelian Randomisation to determine whether lower eGFR has a causal role in CHD. To improve 
the power of MR, we combined 17 SNPs into a single gene score. By using a richly phenotyped data set in the 
UCLEB consortium, we thoroughly examined whether our gene score meets the assumptions of Mendelian 
Randomisation studies, in that it is associated with eGFR, not associated with potential confounders of the 
eGFR-CHD association, and not associated with other biomarkers of CHD that might represent alternative path-
ways than that through eGFR. The gene scores appeared to meet these assumptions although we noted associa-
tions with additional kidney function traits that might represent alternative pathways through kidney function 
to that measured by eGFR.
We found significant evidence of a causal effect on CHD using an unweighted score. However, the weighted 
score revealed that this result is driven by rs653178, which was not associated with eGFR in UCLEB (and there-
fore unreliably down-weighted the significance of the unweighted score). Potential reasons that could cause 
the discrepancy of rs653187 between UCLEB and the previous study by Olden et al. are random sampling, low 
Figure 3. Benjamini-Hochberg adjusted P-values for unweighted and weighted gene score-trait 
associations (N range = 139-15609). Only kidney function traits (eGFR, creatinine, and serum urea 
concentration) are shown to be significantly associated with either gene score (dotted vertical lines). See S5 
Table for further details of summary statistics.
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power due to the smaller sample size in UCLEB, and a substantially weaker association between rs653178 and 
creatinine-based eGFR (p = 1 × 10−4) compared to cystatin-C-based eGFR (p = 3.5 × 10−11)22. Further analyses, 
including taking the direction of effect from external sources rather than the UCLEB data, and selecting study 
participants based on low eGFR, did not yield any stronger evidence of a causal effect.
One explanation of our results is that, if a causal effect exists, it may act only through some pathways con-
tributing to measured eGFR, marked by rs653178, whereas other pathways marked by the other 16 SNPs do not 
have a causal effect. However, rs653178 has been previously shown to be associated with a number of phenotypes, 
including mean arterial pressure26, blood pressure27, celiac disease28 and peripheral artery disease, a known com-
plication of both CHD and CKD29. Therefore the known pleiotropic effect of rs653178 restricts inference of a 
direct causal effect of eGFR on CHD.
Our study has some limitations. Only 1.5% of the variation in eGFR was explained by the gene scores compris-
ing 17 SNPs. In the largest consortium data available, CARDIoGRAMplusC4D including approximately 200,000 
individuals, we would have 74% and 25% power to detect causal odds ratios of 0.9 and 0.95 respectively30, both 
in excess of the observational odds ratio of 0.98 in the UCLEB consortium. Although the study was likely under-
powered over the full range of eGFR, a stronger causal effect may exist among those with eGFR <  60, but our 
gene scores were not associated with CHD among those subjects. A score including more eGFR associated SNPs 
would have more power to detect a causal effect, though at greater risk of violating the MR assumptions. Another 
limitation concerns the validation of the MR assumptions for our gene scores. While UCLEB provides a richly 
phenotyped and large data set, other phenotypes not measured in those studies may be confounding factors or 
show pleiotropic effects of our gene scores. Furthermore our power to detect confounding and pleiotropy was 
reduced by control for multiple testing, which we deemed necessary to avoid falsely inferring that our gene scores 
are invalid instruments.
Observational studies have mainly shown increased risk of CHD among those with low MDRD eGFR com-
pared to those in the normal range. Studies using newer biomarkers provide clear evidence that there is asso-
ciation even at higher eGFR31. We have treated eGFR as a continuous variable in MR analysis, which may have 
reduced power if the causal effect is restricted to subjects with low MDRD eGFR. We took this approach because 
the associated SNPs apparently influence eGFR over its entire range so that a standard MR analysis would corre-
spond to a population-wide intervention on eGFR levels. Again however, we found no association between the 
gene scores and CHD among subjects with low eGFR. More robust methods for MR analysis in discrete exposure 
strata have recently become available25,32 and could be applied here. However, we believe our current results are 
not sufficiently encouraging to warrant these approaches.
We are not the first to observe that inflammatory and thrombotic markers associated with CHD are raised 
in people with CKD5. These potential confounding biomarkers may be a result of other life style associated risk 
factors leading to CKD, in particular overweight at younger age and subsequent obesity33–35. In total we identified 
27 potential confounders but upon adjustment the association between eGFR and CHD remained significant with 
a similar odds ratio. Our power to detect confounders was limited by the number of cases of CHD in UCLEB, 
the range of phenotypes considered (in particular excluding socio-economic status), the limited sample size for 
some particular phenotypes and the multiple testing burden, and further confounders may exist that attenuate or 
abolish the eGFR-CHD association. We used reverse MR to address the possibility of reverse causation, but did 
not observe significant association between a gene score for CHD and levels of eGFR.
In conclusion, this study observed weak evidence for a causal effect of low eGFR on CHD risk, while the 
observational association was not explained by potential confounders nor by reverse causation. However, this 
result was highly influenced by rs653178, which has known pleiotropic effects, therefore restricting any inference 
of a direct causal effect of eGFR on CHD. Our results leave the remaining unexplained association between eGFR 
and CHD as an open question.
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